12.07.2015 Views

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

David P. Langlois (DL 2319) SUTHERLAND ... - FDA Law Blog

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Case 1:09-cv-04665-<strong>DL</strong>C Document 49-2 Filed 03/30/2010 Page 6 of 45what purports to be a copy of the ‘090 patent is attached to the Complaint as Exhibit D. To theextent Paragraph 19 states conclusions of law, no response is required. Except as expresslyadmitted above, Teva denies the allegations in Paragraph 19.20. Upon information and belief, Teva admits that the ‘090 patent, if valid andenforceable, expires on June 19, 2016. Teva further admits that the ‘090 patent lists on its face asan assignee Takeda Chemical Industries, Ltd. Except as expressly admitted above, Teva denies theallegations in Paragraph 20.21. United States Patent No. 6,211,205 (“the ‘205 patent”) speaks for itself. Tevaadmits that the ‘205 patent, entitled “Pharmaceutical Composition,” lists on its face an issue date ofApril 3, 2001 and lists on its face as inventors Hitoshi Ikeda, Takashi Sohda and Hiroyuki Odaka,but specifically denies that the patent was duly issued. Teva further admits that the ‘205 patent listson its face as an assignee Takeda Chemical Industries, Ltd. Teva further admits that what purportsto be a copy of the ‘205 patent is attached to the Complaint as Exhibit E. To the extent Paragraph21 states conclusions of law, no response is required. Except as expressly admitted above, Tevadenies the allegations in Paragraph 21.22. Upon information and belief, Teva admits that the ‘205 patent, if valid andenforceable, expires on June 19, 2016. Teva further admits that the ‘205 patent lists on its face asan assignee Takeda Chemical Industries, Ltd. Except as expressly admitted above, Teva denies theallegations in Paragraph 22.23. United States Patent No. 6,271,243 (“the ‘243 patent”) speaks for itself. Tevaadmits that the ‘243 patent, entitled “Pharmaceutical Composition,” lists on its face an issue date ofAugust 7, 2001 and lists on its face as inventors Hitoshi Ikeda, Takashi Sohda and Hiroyuki Odaka,but specifically denies that the patent was duly issued. Teva further admits that the ‘243 patent lists9067383.15

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!